Pediatrics

MD IQ

News

Cost-effectiveness of CAR T-cell therapy

Tisagenlecleucel has the potential to be cost-effective for pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients in the United States,...

From the Journals

Kymriah appears cost effective in analysis

The latest study on the CAR T therapy tisagenlecleucel for pediatric leukemia says it may be cost effective, provided that the long-term benefits...

Pages